Valuation of cost items during the 12-month follow-up period (in Euro; 2016).</p
<p>Cost-effectiveness plane for the difference in quality of care sum score at 6 months (in Euros).<...
<p>Cost-effectiveness plane for the differences in QALY scores at 6 months (in Euros).</p
Cost rate and availability analysis when follow-up maintenance cost and downtime take the middle val...
Cumulative costs over the 6 months follow-up period by condition (CBTsa vs TAU), in 2015 Euros.</p
Monetary value in shillings of the unmet demand (numbers in brackets) and excess storage at 50 l/c/d...
Eurostat calculates the value of the financial situation in the last 12 months. This is an indicator...
Multiple imputed, unadjusted costs used by participants allocated to the EuroFIT programme immediate...
Total drug cost estimation in active treatment period and post-active treatment period.</p
Change in cost development when prolonging the stay in the Severe stage by one year.</p
Asa-Branca-I costs (USD) based on prices available on the internet in November 2019.</p
Change in cost development when prolonging the stay in the Moderate stage by one or two years.</p
<p>Mean 12 month cost per patient (USD) by outcome and facility, broken down by cost category.</p
<p>Healthcare use/costs, patient and family costs during the nine month follow-up period.</p
Change in cost development when prolonging the stay in the Mild stage by one or two years.</p
<p>The estimation period is <i>J</i> months and the holding period is <i>K</i> months.</p
<p>Cost-effectiveness plane for the difference in quality of care sum score at 6 months (in Euros).<...
<p>Cost-effectiveness plane for the differences in QALY scores at 6 months (in Euros).</p
Cost rate and availability analysis when follow-up maintenance cost and downtime take the middle val...
Cumulative costs over the 6 months follow-up period by condition (CBTsa vs TAU), in 2015 Euros.</p
Monetary value in shillings of the unmet demand (numbers in brackets) and excess storage at 50 l/c/d...
Eurostat calculates the value of the financial situation in the last 12 months. This is an indicator...
Multiple imputed, unadjusted costs used by participants allocated to the EuroFIT programme immediate...
Total drug cost estimation in active treatment period and post-active treatment period.</p
Change in cost development when prolonging the stay in the Severe stage by one year.</p
Asa-Branca-I costs (USD) based on prices available on the internet in November 2019.</p
Change in cost development when prolonging the stay in the Moderate stage by one or two years.</p
<p>Mean 12 month cost per patient (USD) by outcome and facility, broken down by cost category.</p
<p>Healthcare use/costs, patient and family costs during the nine month follow-up period.</p
Change in cost development when prolonging the stay in the Mild stage by one or two years.</p
<p>The estimation period is <i>J</i> months and the holding period is <i>K</i> months.</p
<p>Cost-effectiveness plane for the difference in quality of care sum score at 6 months (in Euros).<...
<p>Cost-effectiveness plane for the differences in QALY scores at 6 months (in Euros).</p
Cost rate and availability analysis when follow-up maintenance cost and downtime take the middle val...
DOI
Add to ORKG